Efficacy and Safety of Dexmedetomidine during Anesthesia Induction of Patients with Intracranial Tumor: A Preliminary Observational Trial

Jiangbei Cao, Wenzhu Shi, Weidong Mi, Hong Zhang

Department of Anesthesiology and Operation Center, PLA General Hospital, Beijing, China.
Department of Anesthesiology and Operation Center, PLA General Hospital, Beijing, China..

DOI: 10.4236/pp.2013.48084                

Abstract

Background: The efficacy and safety of dexmedetomidine during the anesthesia induction of intracranial tumor patients remain unknown. We wondered whether loading infusion of dexmedetomidine 1 μg/kg over 10 min to intracranial tumor patients was as efficient and safe as to those abdominal disease patients. Methods: Patients aged 18-60 years, male or female, ASA I or II, scheduled for intracranial tumor resection (Group N, n = 30) or abdominal operation (Group A, n = 30) were enrolled in this observational trial. Dexmedetomidine was administrated with a loading dosage of 1 μg/kg over 10 min following with continuous infusing of 0.5 μg/kg/h. Fentanyl, propofol and rocuronium were sequentially administered for anesthesia induction. Heart rate (HR), blood pressure (BP), pulse oxygen saturation (SpO2), bispectral index (BIS) and other adverse effects were recorded from the beginning of loading infusion of dexmedetomidine to the end of endotracheal intubation. Results: Among with loading infusion, HR and BIS value decreased and were significantly lower at the end of infusion than before infusion (P < 0.01), but BP did not (P > 0.05). One patient of Group N dropped out from this trial because of a serious headache. 14 of 29 patients during dexmedetomidine loading infusion suffered hypoxemia (SpO2 < 90%) in Group N, which was higher than 6 of 30 of in Group A (P < 0.05). No other side effects were recorded. Conclusion: A loading dosage of 1 μg/kg of dexmedetomidine was not suitable for the anesthesia induction of intracranial tumor patients as compared to patients undergoing abdominal operation.

Keywords

Dexmedetomidine; Intracranial Tumor; Adverse Effects; Loading Infusion

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	R. Siddappa, J. Riggins, S. Kariyanna, P. Calkins and A. T. Rotta, “High-Dose Dexmedetomidine Sedation for Pediatric MRI,” Pediatric Anesthesia, Vol. 21, No. 2, 2011, pp. 153-158. http://dx.doi.org/10.1111/j.1460-9592.2010.03502.x
[2]	S. Strom, “Preoperative Evaluation, Premedication, and Induction of Anesthesia in Infants and Children,” Current Opinion in Anesthesiology, Vol. 25, No. 3, 2012, pp. 321-325. http://dx.doi.org/10.1097/ACO.0b013e3283530e0d
[3]	A. Akin, A. Bayram, A. Esmaoglu, Z. Tosun, R. Aksu, R. Altuntas and A. Boyaci, “Dexmedetomidine vs Midazolam for Premedication of Pediatric Patients Undergoing Anesthesia,” Pediatric Anesthesia, Vol. 22, No. 9, 2012, pp. 871-876. http://dx.doi.org/10.1111/j.1460-9592.2012.03802.x
[4]	A. Patel, M. Davidson, M. C. Tran, H. Quraishi, C. Schoenberg, M. Sant, A. Lin and X. Sun, “Dexmedetomidine Infusion for Analgesia and Prevention of Emergence Agitation in Children with Obstructive Sleep Apnea Syndrome Undergoing Tonsillectomy and Adenoidectomy,” Anesthesia & Analgesia, Vol. 111, No. 4, 2010, pp. 1004-1010.
[5]	N. Ohtani, K. Kida, K. Shoji, Y. Yasui and E. Masaki, “Recovery Profiles from Dexmedetomidine as a General Anesthetic Adjuvant in Patients Undergoing Lower Abdominal Surgery,” Anesthesia & Analgesia, Vol. 107, No. 6, 2008, pp. 1871-1874. http://dx.doi.org/10.1213/ane.0b013e3181887fcc
[6]	K. Kida, N. Ohtani, K. Shoji, Y. Yasui and E. Masaki, “Postoperative Pain Status after Intraoperative Systemic Dexmedetomidine and Epidural Neostigmine in Patients Undergoing Lower Abdominal Surgery,” European Journal of Anaesthesiology, Vol. 25, No. 11, 2008, pp. 869-875. http://dx.doi.org/10.1017/S0265021508004493
[7]	K. P. Mason, D. Zurakowski, S. Zgleszewski, R. Prescilla, P. J. Fontaine and J. A. Dinardo, “Incidence and Predictors of Hypertension during High-Dose Dexmedetomidine Sedation for Pediatric MRI,” Pediatric Anesthesia, Vol. 20, No. 6, 2010, pp. 516-523. http://dx.doi.org/10.1111/j.1460-9592.2010.03299.x
[8]	J. W. Berkenbosch, P. C. Wankum and J. D. Tobias, “Prospective Evaluation of Dexmedetomidine for Noninvasive Procedural Sedation in Children,” Pediatric Critical Care Medicine, Vol. 6, No. 4, 2005, pp. 435-439. http://dx.doi.org/10.1097/01.PCC.0000163680.50087.93
[9]	K. Sato, T. Kimura, T. Nishikawa, Y. Tobe and Y. Masaki, “Neuroprotective Effects of a Combination of Dexmedetomidine and Hypothermia after Incomplete Cerebral Ischemia in Rats,” Acta Anaesthesiologica Scandinavica, Vol. 54, No. 3, 2010, pp. 377-382. http://dx.doi.org/10.1111/j.1399-6576.2009.02139.x
[10]	N. E. Ngwenyama, J. Anderson, D. G. Hoernschemeyer and J. D. Tobias, “Effects of Dexmedetomidine on Propofol and Remifentanil Infusion Rates during Total Intravenous Anesthesia for Spine Surgery in Adolescents,” Pediatric Anesthesia, Vol. 18, No. 2, 2008, pp. 1190-1195.
[11]	R. N. Soliman, A. R. Hassan, A. M. Rashwan and A. M. Omar, “Prospective, Randomized Study to Assess the Role of Dexmedetomidine in Patients with Supratentorial Tumors Undergoing Craniotomy under General Anaesthesia,” Middle East Journal of Anesthesiology, Vol. 21, No. 3, 2011, pp. 325-334.
[12]	M. Schoeler, P. D. Loetscher, R. Rossaint, A. V. Fahlenkamp, G. Eberhardt, S. Rex, J. Weis and M. Coburn, “Dexmedetomidine Is Neuroprotective in an in Vitro Model for Traumatic Brain Injury,” BMC Neurology, Vol. 12, 2012, p. 20. http://dx.doi.org/10.1186/1471-2377-12-20
[13]	S. Dahmani, D. Rouelle, P. Gressens and J. Mantz, “Characterization of the Postconditioning Effect of Dexmedetomidine in Mouse Organotypic Hippocampal Slice Cultures Exposed to Oxygen and Glucose Deprivation,” Anesthesiology, Vol. 112, No. 2, 2010, pp. 373-383. http://dx.doi.org/10.1097/ALN.0b013e3181ca6982
[14]	K. Engelhard, C. Werner, E. Eberspacher, M. Bachl, M. Blobner, E. Hildt, P. Hutzler and E. Kochs, “The Effect of the Alpha 2-Agonist Dexmedetomidine and the n-Methyld-Aspartate Antagonist s(+)-Ketamine on the Expression of Apoptosis-Regulating Proteins after Incomplete Cerebral Ischemia and Reperfusion in Rats,” Anesthesia & Analgesia, Vol. 96, No. 2, 2003, pp. 524-531.
[15]	R. N. Soliman, A. R. Hassan, A. M. Rashwan and A. M. Omar, “Prospective, Randomized Controlled Study to Assess the Role of Dexmedetomidine in Patients with Supratentorial Tumors Undergoing Craniotomy under General Anesthesia,” Middle East Journal of Anesthesiology, Vol. 21, No. 1, 2011, pp. 23-33.
[16]	R. K. Stoelting, “Blood Pressure and Heart Rate Changes during Short-Duration Laryngoscopy for Tracheal Intubation: Influence of Viscous or Intravenous Lidocaine,” Anesthesia & Analgesia, Vol. 57, No. 2, 1978, pp. 197-199. http://dx.doi.org/10.1213/00000539-197803000-00009
[17]	R. A. Allberry and H. F. Drake, “Preoperative Beta-Blockade for Patients Undergoing Craniotomy: A Comparison between Propranolol and Atenolol,” Canadian Journal of Anaesthesia, Vol. 37, No. 4, 1990, pp. 448-451. http://dx.doi.org/10.1007/BF03005625
[18]	W. S. Kang, S. Y. Kim, J. C. Son, J. D. Kim, H. B. Muhammad, S. H. Kim, T. G. Yoon and T. Y. Kim, “The Effect of Dexmedetomidine on the Adjuvant Propofol Requirement and Intraoperative Hemodynamics during Remifentanil-Based Anesthesia,” Korean Journal of Anesthesiology, Vol. 62, No. 2, 2012, pp. 113-118. http://dx.doi.org/10.4097/kjae.2012.62.2.113
[19]	Z. Ozkose, F. S. Demir, K. Pampal and S. Yardim, “Hemodynamic and Anesthetic Advantages of Dexmedetomidine, an Alpha 2-Agonist, for Surgery in Prone Position,” Tohoku Journal of Experimental Medicine, Vol. 210, No. 2, 2006, pp. 153-160. http://dx.doi.org/10.1620/tjem.210.153
[20]	S. R. Arain and T. J. Ebert, “The Efficacy, Side Effects, and Recovery Characteristics of Dexmedetomidine versus Propofol When Used for Intraoperative Sedation,” Anesthesia & Analgesia, Vol. 95, No. 2, 2002, pp. 461-466.
[21]	R. Y. Klinger, W. D. White, B. Hale, A. S. Habib and E. Bennett-Guerrero, “Hemodynamic Impact of Dexmedetomidine Administration in 15,656 Noncardiac Surgical Cases,” Journal of Clinical Anesthesia, Vol. 24, No. 3, 2012, pp. 212-220. http://dx.doi.org/10.1016/j.jclinane.2011.07.016
[22]	M. Shukry and J. A. Miller, “Update on Dexmedetomidine: Use in Nonintubated Patients Requiring Sedation for Surgical Procedures,” Therapeutics and Clinical Risk Management, Vol. 6, 2010, pp. 111-121. http://dx.doi.org/10.2147/TCRM.S5374
[23]	A. Bekker, M. Sturaitis, M. Bloom, M. Moric, J. Golfinos, E. Parker, R. Babu and A. Pitti, “The Effect of Dexmedetomidine on Perioperative Hemodynamics in Patients Undergoing Craniotomy,” Anesthesia & Analgesia, Vol. 107, No. 4, 2008, pp. 1340-1347. http://dx.doi.org/10.1213/ane.0b013e3181804298
[24]	M. A. Mirski, Lewin Jr., S. Ledroux, C. Thompson, P. Murakami, E. K. Zink and M. Griswold, “Cognitive Improvement during Continuous Sedation in Critically Ill, Awake and Responsive Patients: The Acute Neurological ICU Sedation Trial (Anist),” Intensive Care Medicine, Vol. 36, No. 9, 2010, pp. 1505-1513. http://dx.doi.org/10.1007/s00134-010-1874-9
[25]	A. Bekker and M. K. Sturaitis, “Dexmedetomidine for Neurological Surgery,” Neurosurgery, Vol. 57, No. 1, 2005, pp. 1-10. http://dx.doi.org/10.1227/01.NEU.0000163476.42034.A1
[26]	M. Cosar, O. Eser, H. Fidan, O. Sahin, S. Buyukbas, Y. Ela, M. Yagmurca and O. A. Ozen, “The Neuroprotective Effect of Dexmedetomidine in the Hippocampus of Rabbits after Subarachnoid Hemorrhage,” Surgical Neurology, Vol. 71, No. 1, 2009, pp. 54-59. http://dx.doi.org/10.1016/j.surneu.2007.08.020
[27]	J. C. Drummond, A. V. Dao, D. M. Roth, C. R. Cheng, B. I. Atwater, A. Minokadeh, L. C. Pasco and P. M. Patel, “Effect of Dexmedetomidine on Cerebral Blood Flow Velocity, Cerebral Metabolic Rate, and Carbon Dioxide Response in Normal Humans,” Anesthesiology, Vol. 108, No. 2, 2008, pp. 225-232. http://dx.doi.org/10.1097/01.anes.0000299576.00302.4c
[28]	A. S. Uyar, H. Yagmurdur, Y. Fidan, C. Topkaya and H. Basar, “Dexmedetomidine Attenuates the Hemodynamic and Neuroendocrinal Responses to Skull-Pin Head-Holder Application during Craniotomy,” Journal of Neurosurgical Anesthesiology, Vol. 20, No. 3, 2008, pp. 174-179. http://dx.doi.org/10.1097/ANA.0b013e318177e5eb
[29]	I. Rozet, “Anesthesia for Functional Neurosurgery: The Role of Dexmedetomidine,” Current Opinion in Anaesthesiology, Vol. 21, No. 5, 2008, pp. 537-543. http://dx.doi.org/10.1097/ACO.0b013e32830edafd
[30]	P. O. Talke and M. Maze, “Expecting the Unexpected,” Anesthesia & Analgesia, Vol. 106, No. 6, 2008, pp. 1605-1606. http://dx.doi.org/10.1213/ane.0b013e31816c3f69
[31]	M. Venn, J. Newman and M. Grounds, “A Phase II Study to Evaluate the Efficacy of Dexmedetomidine for Sedation in the Medical Intensive Care Unit,” Intensive Care Medicine, Vol. 29, No. 2, 2003, pp. 201-207.
[32]	J. D. Tobias, J. W. Berkenbosch and P. Russo, “Additional Experience with Dexmedetomidine in Pediatric Patients,” Southern Medical Journal, Vol. 96, No. 9, 2003, pp. 871-875. http://dx.doi.org/10.1097/01.SMJ.0000053557.75799.09
[33]	J. D. Tobias and J. W. Berkenbosch, “Sedation during Mechanical Ventilation in Infants and Children: Dexmedetomidine versus Midazolam,” Southern Medical Journal, Vol. 97, No. 5, 2004, pp. 451-455. http://dx.doi.org/10.1097/00007611-200405000-00007
[34]	K. P. Mason, D. Zurakowski, S. E. Zgleszewski, C. D. Robson, M. Carrier, P. R. Hickey and J. A. Dinardo, “High Dose Dexmedetomidine as the Sole Sedative for Pediatric MRI,” Pediatric Anesthesia, Vol. 18, No. 5, 2008, pp. 403-411. http://dx.doi.org/10.1111/j.1460-9592.2008.02468.x
[35]	K. P. Mason, S. Zgleszewski, R. E. Forman, C. Stark and J. A. DiNardo, “An Exaggerated Hypertensive Response to Glycopyrrolate Therapy for Bradycardia Associated with High-Dose Dexmedetomidine,” Anesthesia & Anal-gesia, Vol. 108, No. 3, 2009, pp. 906-908. http://dx.doi.org/10.1213/ane.0b013e3181948a6f